Actively Recruiting
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
Led by Wenjin Yin · Updated on 2025-11-19
229
Participants Needed
1
Research Sites
387 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
CONDITIONS
Official Title
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 and older
- Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence
- Hormone receptor-positive and HER2-negative breast cancer
- ECOG performance status of 0 to 3
- Meeting current guideline recommendations and planning to receive adjuvant CDK4/6 inhibitors
You will not qualify if you...
- Pregnancy or breastfeeding
- Unable to swallow tablets or have gastrointestinal absorption problems
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China, 200127
Actively Recruiting
Research Team
W
Wenjin Yin, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here